Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.
Alexey V. Danilov, MD, PhD, associate professor of medicine at the Oregon Health & Science University, discusses important studies in the chronic lymphocytic leukemia (CLL) space and questions whether combination or sequential therapy is better for patients with CLL.
Danilov says that in this new era of medicine, chemotherapy will be used less, and now the question at hand is whether patients with CLL can achieve deep responses on regimens with finite durations. At the 2019 American Society of Hematology (ASH) Annual Meeting, studies of ibrutinib (Imbruvica) plus venetoclax (Venclexta), and acalabrutinib (Calquence) plus venetoclax, with or without a CD20 antibody, were exhibited.
The AVO study of acalabrutinib, venetoclax, and obinutuzumab (Gazyva) was presented by Benjamin L. Lampson, MD, PhD, and Matthew S. Davids, MD. It demonstrated good efficacy through high response rates and high durability in patients with CLL. There were a percentage of patients with bone marrow minimal residual disease after 6 months, according to Danilov. Nitin Jain, MD, presented patients with treatment naïve CLL who showed high response rates with ibrutinib and venetoclax at ASH.
Danilov wonders if combination therapy is necessary for all patients with CLL or if combination therapy with novel agents can result in prolonged progression-free survival or overall survival compared to single-agent therapy. Longer follow-up is required for combination regimens in clinical trials to determine if physicians should use combination therapy versus sequential therapy.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More